Recent studies have provided evidence that MYC activation contributes to lung adenocarcinoma progression in KRASG12D-driven lung tumors in vivo, showing that MYC drives the conversion of indolent adenomas to aggressive, inflammatory, and immune-suppressed adenocarcinomas; MYC deactivation in these tumors causes tumor regression [242]. The gene discussed is MYC; the disease is neoplasm.